Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181124 | 0.88 | OPRD1 (0.33) | OPRD1SMOPYGL | |
| SCHEMBL19999770 | 0.87 | PER2 (0.34) | PER2CRY1CRY2GPR139 | |
| SCHEMBL19999757 | 0.81 | FPR1 (0.37) | PYGL | |
| SCHEMBL18057235 | 0.81 | PYGL (0.33) | PER2CRY1CRY2PYGL | |
| SCHEMBL18057239 | 0.81 | KCNH2 (0.38) | PER2CRY1CRY2PYGL | |
| SCHEMBL19999755 | 0.81 | — | — | |
| SCHEMBL19999773 | 0.79 | PIN1 (0.32) | PER2CRY1CRY2PYGL | |
| SCHEMBL19999768 | 0.79 | — | — | |
| SCHEMBL19999759 | 0.79 | NPY1R (0.36) | PYGL | |
| SCHEMBL19999763 | 0.78 | PYGL (0.37) | PER2CRY1CRY2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | OPRD1 2975/4885SMO 4626/4885PER2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.